opt shareholders deserve a conference call, page-21

Megan’s 3 decade long science career is probably toast along with Fred.
Nope!

Sozinibercept has a strong safety profile so allowing Ophthalmologists to prescribe Sozinibercept to patients who have had a poor response to the SoC won't be an issue it either helps or it doesn't, based on the real world feedback of Ophthalmologists & KOLs over a defined period the FDA could either confirm the Marketing Authorization or withdraw it.
Nope!
Just because its safe does not mean it should be used. Its no better than a saline injection. Opthea need to do other trials to prove that what happened was a fluke x 2, or even fraud.